Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Sajith Kumar & Bhavani Shankara Bagepally. (2023) Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-14.
Read now
Read now
Eiichi Tanaka, Eisuke Inoue, Rei Yamaguchi, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Daisuke Hoshi, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2017) Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Modern Rheumatology 27:2, pages 227-236.
Read now
Read now
Francis Fagnani, Thao Pham, Pascal Claudepierre, Francis Berenbaum, Thibault De Chalus, Carine Saadoun, Jean-Michel Joubert & Bruno Fautrel. (2016) Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France. Journal of Medical Economics 19:8, pages 812-821.
Read now
Read now
Alberto Migliore, Emanuele Bizzi, Colin Gerard Egan, Mauro Bernardi & Lea Petrella. (2015) Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Therapeutics and Clinical Risk Management 11, pages 1325-1335.
Read now
Read now
J. Heinonen, T.H. Koskela, E. Soini & O.P. Ryynänen. (2015) Primary-care-based episodes of care and their costs in a three-month follow-up in Finland. Scandinavian Journal of Primary Health Care 33:4, pages 283-290.
Read now
Read now
Eiichi Tanaka, Eisuke Inoue, Daisuke Hoshi, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2015) Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Modern Rheumatology 25:4, pages 503-513.
Read now
Read now
Michael L. Ganz, Brian Bekker Hansen, Xavier Valencia & Martin Strandberg-Larsen. (2015) Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis. Journal of Medical Economics 18:5, pages 366-375.
Read now
Read now
Toshio Tanaka, Yoshihiro Hishitani & Atsushi Ogata. (2014) Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics: Targets and Therapy 8, pages 141-153.
Read now
Read now
Articles from other publishers (30)
Hai-Binh Bui, Hong-Thinh Lai, Thanh-Lam Nguyen, Thuy-Duong Vu, Nhat-Le Bui, Van-Hung Nguyen, Thi-To-Chau Tran, Thi-Phuong-Thuy Nguyen, Thi-Ngoc-Lan Nguyen, Jaffar A. Al-Tawfiq & Dinh-Toi Chu. (2023) The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam. Reumatología Clínica.
Crossref
Crossref
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes WJ Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L Hyrich, Annamaria Iagnocco, John D Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka & Josef S Smolen. (2023) Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the Rheumatic Diseases 82:6, pages 773-787.
Crossref
Crossref
Masataka Kuwana, Naoto Tamura, Shinsuke Yasuda, Keishi Fujio, Ayako Shoji, Hiroko Yamaguchi, Katsuhiko Iwasaki, Misako Makishima, Yuichi Kawata, Katsuhisa Yamashita & Ataru Igarashi. (2023) Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. Modern Rheumatology 33:2, pages 302-311.
Crossref
Crossref
Hisashi Yamanaka, Mitsumasa Kishimoto, Nobuo Nishijima, Katsuhisa Yamashita, Junnosuke Matsushima, Jacqueline O’Brien, Taylor Blachley, Melissa Eliot, Zachary Margolin, Swapna S Dave & Yoshiya Tanaka. (2023) Socioeconomic impact of treatment with biological disease–modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis. Modern Rheumatology.
Crossref
Crossref
Akira Yuasa, Naohiro Yonemoto, Kazumasa Kamei, Toshiaki Murofushi, Michael LoPresti, Ankush Taneja, Jake Horgan & Shunya Ikeda. (2022) Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders. Advances in Therapy 39:12, pages 5327-5350.
Crossref
Crossref
Eiichi Tanaka, Eisuke Inoue, Ayako Shoji, Jonas Nilsson, Christos Papagiannopoulos, Devender Dhanda, Yuri Yoshizawa, Mai Abe, Kumiko Saka, Eri Sugano, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka & Masayoshi Harigai. (2022) Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. PLOS ONE 17:11, pages e0277566.
Crossref
Crossref
Abe Dunn, Anne Hall & Seidu Dauda. (2022) Are Medical Care Prices Still Declining? A Re‐Examination Based on Cost‐Effectiveness Studies. Econometrica 90:2, pages 859-886.
Crossref
Crossref
Ahmad Gholami, Jassem Azizpoor, Elham Aflaki, Mehdi Rezaee & Khosro Keshavarz. (2021) Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept. BioMed Research International 2021, pages 1-12.
Crossref
Crossref
Emma Sullivan, Jim Kershaw, Stuart Blackburn, Puneet Mahajan & Susan H. Boklage. (2020) Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. Rheumatology and Therapy 7:3, pages 517-535.
Crossref
Crossref
Salah Ghabri, Laurent Lam, François Bocquet & Hans-Martin Spath. (2020) Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs. PharmacoEconomics 38:5, pages 459-471.
Crossref
Crossref
Zhi-Chao Shi, Hong-Ping Fei & Zhi-Liang Wang. (2020) Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients. Medicine 99:3, pages e16635.
Crossref
Crossref
Pauline Binder‐Finnema, Kathryn Dzurilla, Betty Hsiao & Liana Fraenkel. (2019) Qualitative Exploration of Triangulated, Shared Decision‐Making in Rheumatoid Arthritis. Arthritis Care & Research 71:12, pages 1576-1582.
Crossref
Crossref
Feng Tian, Jing-Yang Li, Zhen-Hua Wen, Xiao-Wen Luo, Li Deng, Liang Zhang & Jing-Yun He. (2019) A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients. Medicine 98:48, pages e17750.
Crossref
Crossref
Erkki Soini, Christian Asseburg, Maarit Taiha, Kari Puolakka, Oana Purcaru & Riitta Luosujärvi. (2017) Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. Advances in Therapy 34:10, pages 2316-2332.
Crossref
Crossref
Sun-Kyeong Park, Seung-Hoo Park, Min-Young Lee, Ji-Hyun Park, Jae-Hong Jeong & Eui-Kyung Lee. (2016) Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical Therapeutics 38:11, pages 2430-2446.e3.
Crossref
Crossref
Naonobu Sugiyama, Yutaka Kawahito, Takao Fujii, Tatsuya Atsumi, Tatsunori Murata, Yosuke Morishima & Yuri Fukuma. (2016) Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. Clinical Therapeutics 38:6, pages 1359-1375.e1.
Crossref
Crossref
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young & Allan Wailoo. (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment 20:35, pages 1-610.
Crossref
Crossref
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Martina Biggioggero, Maurizio Benucci, Francesca Li Gobbi, Valentina Grossi, Maria Infantino, Francesca Meacci, Mariangela Manfredi, Serena Guiducci, Silvia Bellando-Randone, Marco Matucci-Cerinic, Rosario Foti, Marcella Di Gangi, Marta Mosca, Chiara Tani, Fabrizio Palmieri & Delia Goletti. (2016) Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 45:5, pages 519-532.
Crossref
Crossref
Álvaro Hidalgo-Vega, Renata Villoro, Juan Antonio Blasco, Pablo Talavera, Belén Ferro & Oana Purcaru. (2015) Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. Cost Effectiveness and Resource Allocation 13:1.
Crossref
Crossref
Marieke Krol & Werner Brouwer. (2015) Unpaid work in health economic evaluations. Social Science & Medicine 144, pages 127-137.
Crossref
Crossref
Min-Young Lee, Sun-Kyeong Park, Sun-Young Park, Ji-Hye Byun, Sang-Min Lee, Su-Kyoung Ko & Eui-Kyung Lee. (2015) Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. Clinical Therapeutics 37:8, pages 1662-1676.e2.
Crossref
Crossref
Jaana T. Joensuu, Saara Huoponen, Kalle J. Aaltonen, Yrjö T. Konttinen, Dan Nordström & Marja Blom. (2015) The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review. PLOS ONE 10:3, pages e0119683.
Crossref
Crossref
Stefan Scholz & Thomas Mittendorf. (2014) Modeling rheumatoid arthritis using different techniques - a review of model construction and results. Health Economics Review 4:1.
Crossref
Crossref
Jonathan Tosh, Matt Stevenson & Ron Akehurst. (2014) Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review. Current Rheumatology Reports 16:10.
Crossref
Crossref
H. G. M. van Haalen, J. L. Severens, A. Tran-Duy & A. Boonen. (2014) How to Select the Right Cost-Effectiveness Model?. PharmacoEconomics 32:5, pages 429-442.
Crossref
Crossref
Sohita Dhillon. (2013) Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis. BioDrugs 28:1, pages 75-106.
Crossref
Crossref
Erkki J Soini, Miina Leussu & Taru Hallinen. (2013) Administration costs of intravenous biologic drugs for rheumatoid arthritis. SpringerPlus 2:1.
Crossref
Crossref
Florian MP Meier, Marc Frerix, Walter HermannUlf Müller-Ladner. (2013) Current immunotherapy in rheumatoid arthritis. Immunotherapy 5:9, pages 955-974.
Crossref
Crossref
Helen Dakin. (2013) Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health and Quality of Life Outcomes 11:1, pages 151.
Crossref
Crossref
Nicole W. Tsao, Nick J. Bansback, Kam Shojania & Carlo A. Marra. (2012) The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 26:5, pages 659-676.
Crossref
Crossref